☰

Kamlesh K. Yadav, Ph.D. - Publications

Affiliations: 
2011 Basic Medical Science New York University, New York, NY, United States 
Area:
Biochemistry, Molecular Biology, Cell Biology
Tree Info Similar researchers PubMed Report error

29 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Woo J, Santasusagna S, Banks J, Pastor-Lopez S, Yadav K, Carceles-Cordon M, Dominguez-Andres A, Den RB, Languino L, Pippa R, Lallas CD, Luyao G, Kelly WK, Knudsen KE, Rodriguez-Bravo V, et al. Urine Extracellular Vesicle GATA2 mRNA Discriminates Biopsy Result in Men with Suspicion of Prostate Cancer. The Journal of Urology. 101097JU000000000000. PMID 32250729 DOI: 10.1097/Ju.0000000000001066  0.398
2019 Mohamed NE, Tewari AK, Yadav KK. Development and validation of a polygenic hazard score for aggressive prostate cancer identification Translational Cancer Research. 8. DOI: 10.21037/25668  0.387
2019 Woo J, Santasusagna S, Leiby B, Yadav KK, Dominguez-Andres A, Pippa R, Wang KR, Carceles-Cordon M, Fields S, Weil R, Stolovitzky GA, Tewari A, Lu-Yao GL, Kelly WK, Rodriguez-Bravo V, et al. GATA2 exosomal mRNA: A novel urine biomarker for the diagnosis of clinically significant prostate cancer. Journal of Clinical Oncology. 37: 18-18. DOI: 10.1200/Jco.2019.37.7_Suppl.18  0.366
2019 Woo J, Santasusagna S, Banks J, Dominguez-Andres A, Yadav K, Pippa R, Carceles-Cordon M, Lallas C, Luyao G, Rodriguez-Bravo V, Tewari A, Pastor-Lopez S, Kelly W, Leiby B, Prats J, et al. Urine extracellular vesicle GATA2 mRNA alone and in a multigene test predicts initial prostate biopsy result Annals of Oncology. 30: v349. DOI: 10.1093/Annonc/Mdz248.044  0.402
2018 Beksac AT, Cumarasamy S, Falagario U, Xu P, Takhar M, Alshalalfa M, Gupta A, Prasad S, Martini A, Thulasidass H, Rai R, Berger M, Hectors S, Jordan J, Davicioni E, ... ... Yadav K, et al. Multiparametric Magnetic Resonance Imaging Features Identify Aggressive Prostate Cancer at the Phenotypic and Transcriptomic Level. The Journal of Urology. 200: 1241-1249. PMID 30563651 DOI: 10.1016/J.Juro.2018.06.041  0.358
2018 Olsson CA, Lavery HJ, Yadav KK, Anderson AE, Kapoor D. Histologic Changes in Prostate Cancer Detected Subsequent to the 2012 United States Preventive Services Task Force (USPSTF) Prostate Cancer Screening Recommendation. Reviews in Urology. 20: 125-130. PMID 30473638 DOI: 10.3909/Riu0815  0.387
2018 Yadav KK. How AI Is Optimizing the Detection and Management of Prostate Cancer. Ieee Pulse. 9: 19. PMID 30273137 DOI: 10.1109/Mpul.2018.2866354  0.403
2018 Tewari AK, Stockert JA, Yadav SS, Yadav KK, Khan I. Inflammation and Prostate Cancer. Advances in Experimental Medicine and Biology. 1095: 41-65. PMID 30229548 DOI: 10.1007/978-3-319-95693-0_3  0.396
2018 Hieronymus H, Murali R, Tin A, Yadav K, Abida W, Moller H, Berney D, Scher H, Carver B, Scardino P, Schultz N, Taylor B, Vickers A, Cuzick J, Sawyers CL. Tumor copy number alteration burden is a pan-cancer prognostic factor associated with recurrence and death. Elife. 7. PMID 30178746 DOI: 10.7554/Elife.37294  0.372
2018 Yadav SS, Stockert JA, Hackert V, Yadav KK, Tewari AK. Intratumor heterogeneity in prostate cancer. Urologic Oncology. PMID 29887240 DOI: 10.1016/J.Urolonc.2018.05.008  0.366
2018 Yadav KK, Shameer K, Stockert JA, Elaiho C, Readhead B, Yadav SS, Dudley J, Tewari AK. Abstract B023: Identification and biochemical validation of piperlongumine as a potent therapeutic against neuroendocrine prostate cancer Cancer Research. 78. DOI: 10.1158/1538-7445.Prca2017-B023  0.378
2018 Rayford W, Alger J, Takhar M, Jordan J, Yadav K, Alshalalfa M, Dai D, Fishbane N, Scott T, Collins J, Bender B, Ahmed M, Lehrer J, Erho N, Davicioni E, et al. PD56-01 COMPARATIVE GENOMIC ANALYSIS OF 1,043 AFRICAN AMERICAN AND NON-AFRICAN AMERICAN PROSTATE CANCERS: A REPORT FROM THE DECIPHER GRID COLLABORATIVE Journal of Urology. 199. DOI: 10.1016/J.Juro.2018.02.2633  0.329
2017 Yadav SS, Li J, Stockert JA, Herzog B, O'Connor J, Garzon-Manco L, Parsons R, Tewari AK, Yadav KK. Induction of Neuroendocrine Differentiation in Prostate Cancer Cells by Dovitinib (TKI-258) and its Therapeutic Implications. Translational Oncology. 10: 357-366. PMID 28342996 DOI: 10.1016/J.Tranon.2017.01.011  0.417
2017 Shameer K, Yadav KK, Li L, Yadav SS, Glicksberg B, Khan I, Johnson KW, Badgeley MA, Elaiho C, Readhead B, Kidd BA, Kasarskis A, Dudley JT, Tewari AK. Abstract 3772: A multi-scale survey to assess the impact of inflammatory diseases of the abdominal cavity and prostate cancer severity Cancer Research. 77: 3772-3772. DOI: 10.1158/1538-7445.Am2017-3772  0.406
2017 Yadav KK, Shameer K, Readhead B, Stockert JA, Elaiho C, Yadav SS, Glicksberg BS, Johnson KW, Becker C, Kasarskis A, Tewari AK, Dudley JT. Abstract 3250: Computational drug repositioning and biochemical validation of piperlongumine as a potent therapeutic agent for neuroendocrine prostate cancer Cancer Research. 77: 3250-3250. DOI: 10.1158/1538-7445.Am2017-3250  0.391
2017 Yadav KK, Shameer K, Yadav SS, Elaiho C, Li L, O'Connor J, Glicksberg B, Jhonson K, Badgeley M, Readhead B, Kidd B, Kasarskis A, Dudley J, Tewari A. MP14-08 A MULTISCALE SURVEY OF INFLAMMATORY DISEASES AND PROSTATE ONCOPHENOTYPES. Journal of Urology. 197. DOI: 10.1016/J.Juro.2017.02.472  0.351
2017 Rai R, Elaiho C, Hackert V, Yadav KK, Tewari A, Yadav SS. Mp87-09 Distinct Epigenetic And Transcriptomic Variations In African American Men As Compared To Caucasian In Prostate Cancer The Journal of Urology. 197. DOI: 10.1016/J.Juro.2017.02.2713  0.386
2017 Yadav KK, Shameer K, Stockert J, Elaiho C, Readhead B, Yadav SS, Dudley J, Tewari A. PD37-10 BIOCHEMICAL VALIDATION OF PIPERLONGUMINE AS A POTENT THERAPEUTIC AGAINST NEUROENDOCRINE PROSTATE CANCER Journal of Urology. 197. DOI: 10.1016/J.Juro.2017.02.1572  0.364
2017 Stockert J, Yadav SS, Tewari A, Yadav KK. Mp33-09 Clinical Utility Of Pseudouridine As A Diagnostic Marker To Detect Prostate Cancer The Journal of Urology. 197. DOI: 10.1016/J.Juro.2017.02.1005  0.388
2016 Yadav SS, Li J, Stockert JA, O'Connor J, Herzog B, Elaiho C, Galsky MD, Tewari AK, Yadav KK. Combination effect of therapies targeting the PI3K- and AR-signaling pathways in prostate cancer. Oncotarget. PMID 27783994 DOI: 10.18632/Oncotarget.12771  0.338
2016 Christensen SM, Tu HL, Jun JE, Alvarez S, Triplet MG, Iwig JS, Yadav KK, Bar-Sagi D, Roose JP, Groves JT. One-way membrane trafficking of SOS in receptor-triggered Ras activation. Nature Structural & Molecular Biology. PMID 27501536 DOI: 10.1038/Nsmb.3275  0.505
2016 Yadav KK, Khader S, Readhead B, Yadav SS, Li L, Kasarksis A, Tewari AK, Dudley JT. Systems Medicine approaches to improving understanding, treatment, and clinical management of Neuroendocrine Prostate Cancer. Current Pharmaceutical Design. PMID 27174811 DOI: 10.2174/1381612822666160513145924  0.407
2016 Yadav SS, Li J, Herzog B, Stockert J, O'Connor J, Garzon Manco L, Elaiho C, Haines K, Tewari AK, Yadav KK. MP90-11 INDUCTION OF NEUROENDOCRINE DIFFERENTIATION IN PROSTATE CANCER CELLS BY DOVITINIB (TKI-258) AND ITS ASSOCIATED THERAPEUTIC IMPLICATIONS Journal of Urology. 195. DOI: 10.1016/S1569-9056(17)30168-9  0.414
2016 Li J, Yadav SS, O'Connor J, Herzog B, Elaiho C, Yadav KK, Tewari AK. PD32-09 COMBINATION EFFECT OF THERAPIES TARGETING THE PI3K-MTOR AND AR SIGNALING PATHWAYS IN PROSTATE CANCER Journal of Urology. 195. DOI: 10.1016/J.Juro.2016.02.685  0.361
2015 Yadav SS, Li J, Lavery HJ, Yadav KK, Tewari AK. Next-generation sequencing technology in prostate cancer diagnosis, prognosis, and personalized treatment. Urologic Oncology. 33: 267.e1-13. PMID 25791755 DOI: 10.1016/J.Urolonc.2015.02.009  0.413
2011 Patgiri A, Yadav KK, Arora PS, Bar-Sagi D. An orthosteric inhibitor of the Ras-Sos interaction. Nature Chemical Biology. 7: 585-7. PMID 21765406 DOI: 10.1038/Nchembio.612  0.509
2010 Yadav KK, Bar-Sagi D. Allosteric gating of Son of sevenless activity by the histone domain. Proceedings of the National Academy of Sciences of the United States of America. 107: 3436-40. PMID 20133694 DOI: 10.1073/Pnas.0914315107  0.513
2007 Tartaglia M, Pennacchio LA, Zhao C, Yadav KK, Fodale V, Sarkozy A, Pandit B, Oishi K, Martinelli S, Schackwitz W, Ustaszewska A, Martin J, Bristow J, Carta C, Lepri F, et al. Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome. Nature Genetics. 39: 75-9. PMID 17143282 DOI: 10.1038/Ng1939  0.521
2007 Tartaglia M, Pennacchio LA, Zhao C, Yadav KK, Fodale V, Sarkozy A, Pandit B, Oishi K, Martinelli S, Schackwitz W, Ustaszewska A, Martin J, Bristow J, Carta C, Lepri F, et al. Erratum: Corrigendum: Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome Nature Genetics. 39: 276-276. DOI: 10.1038/Ng0207-276A  0.478
Show low-probability matches.